Categories Earnings, Other Industries

Pfizer’s dilemma: To sell or not to sell

Pfizer (PFE) has been contemplating on selling its consumer healthcare division for some time, and it had found two bidders — British pharmaceutical giants GlaxoSmithKline and Reckitt Benckiser. However, with Reckitt announcing its decision to back out of the race yesterday to pursue its $16.6 billion integration of Mead Johnson Nutrition, Pfizer is left with little to negotiate.

Though other companies including Johnson & Johnson (JNJ), Sanofi (SNY) and Nestle had shown interest in the initial stages of bidding, they later decided not to pursue the race for the unit that sells dietary supplement Centrum and pain reliever Advil among other popular products.

The unit, which is valued at around $20 billion, was put on sale by Pfizer to streamline more investment to the R&D of prescription drugs. Though the consumer segment is a lucrative area given the aging population as well as the rising trend of self-medication, the unit had become a slow-growth segment due to intense competition from generic drugs and online sales.

Image courtesy : Norbert Nagel, Wikimedia Commons

Ibrance is still the star

Lack of a solid pipeline of drugs in a market that is stuffed with generic alternatives and biosimilars is what worries Pfizer the most at the moment. The oncology segment is the strongest and is likely to see a growth of 20% this year, thanks to Ibrance. The drug, which is used to treat breast cancer, is expected to post sales of about $3.8 billion by the end of this year.

Apart from this, there is hardly anything to be positive about the company since a number of other popular drugs are nearing patent expiry. Meanwhile, earnings are expected to see double-digit growth this year helped by the recent tax reform, while revenue is predicted to increase 3.5%.

A sale would help the company divert more funds to the growth areas, but only if the expected terms are met. Otherwise, the consumer segment is not detrimental in any way since the company has strong cash flow and balance sheet.

Most Popular

Earnings Preview: What to look for when Broadcom (AVGO) reports Q1 results

Broadcom, Inc. (NASDAQ: AVGO) will be releasing its first-quarter results next week. Over the years, the company constantly broadened its portfolio beyond semiconductors to areas like enterprise software solutions, a

Here’s a look at Lowe’s (LOW) expectations for the near term and ahead

Shares of Lowe’s Companies, Inc. (NYSE: LOW) were up over 1% on Friday. The stock has gained 19% over the past three months. The home improvement retailer saw sales and

TJX Companies (TJX) Q4 2024 profit jumps on strong revenue growth

The TJX Companies, Inc. (NYSE: TJX) has reported a double-digit increase in net income for the fourth quarter of 2024 when the fashion retailer's net sales grew 13%. Fourth-quarter sales

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top